Trial · NCT00637806
Treatment of Cancer-associated Anorexia Using Megestrol Acetate Concentrated Suspension
NCT00637806, Phase 3, Terminated, Par Pharmaceutical, Inc.; results first posted 2016-05-02
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Treatment of Cancer-associated Anorexia Using Megestrol Acetate Concentrated Suspension. Trials, record NCT00637806. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00637806
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Treatment of Cancer-associated Anorexia Using Megestrol Acetate Concentrated Suspension
- NCT number
- NCT00637806
- Status
- Terminated
- Phases
- Phase 3
- Enrollment
- 4 participants, actual
- Lead sponsor
- Par Pharmaceutical, Inc.
- Conditions
- Anorexia, Cachexia, Weight Loss
- Interventions
- Megestrol acetate concentrated suspension 110 mg/mL, Megestrol acetate concentrated suspension 60 mg/mL, Placebo
- First posted
- 2008-03-18
- Last updated
- 2016-05-02
- Results first posted
- 2016-05-02
Source ClinicalTrials.gov
Registered outcomes4
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Average Daily Caloric Intake Over the Course of the 8-week Double-blind Phase | 8 weeks | The Nutrition Data System for Research (NDSR) was used to determine nutrient and caloric value for foods and beverages consumed and recorded by subjects over a 3-day assessment period prior to each visit. Total number of calories consumed during each 3-day assessment was averaged over available values to determine the week's daily caloric intake value. |
| Secondary | Change in Weight Over the Course of the 8-week Double-blind Phase | Baseline, Week 1, 2, 3, 4, 6, and 8 | |
| Secondary | Changes in Body Composition as Measured by Bioelectric Impedance Analysis (BIA) at Week 4 and Week 8 Relative to Baseline | Baseline, Week 4 and Week 8 | |
| Secondary | Change in Appetite Over the 8-week Double-blind Phase as Measured by a VAS Appetite Scale | Baseline, Weeks 1, 2, 3, 4, 6 and 8 | Subjects marked 6 items on a visual analog scale (VAS) appetite scale including feeling not hungry to hungry, not nauseated to nauseated, empty to full, not satiated to satiated; weak to strong desire to eat; and ability to eat none to a large amount of food |
Source ClinicalTrials.gov
Outcomes4
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Average Daily Caloric Intake Over the Course of the 8-week Double-blind Phase | 8 weeks | Results not analyzed due to early termination of the study | ||
| SECONDARY | Change in Weight Over the Course of the 8-week Double-blind Phase | Baseline, Week 1, 2, 3, 4, 6, and 8 | Results not analyzed due to early termination of the study | ||
| SECONDARY | Changes in Body Composition as Measured by Bioelectric Impedance Analysis (BIA) at Week 4 and Week 8 Relative to Baseline | Baseline, Week 4 and Week 8 | Results not analyzed due to early termination of the study | ||
| SECONDARY | Change in Appetite Over the 8-week Double-blind Phase as Measured by a VAS Appetite Scale | Baseline, Weeks 1, 2, 3, 4, 6 and 8 | Results not analyzed due to early termination of the study |
Source ClinicalTrials.gov
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow24
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Double-blind Phase | STARTED | DB MA-CS 550 mg/Day | 2 | |
| Double-blind Phase | STARTED | DB MA-CS 300 mg/Day | 0 | |
| Double-blind Phase | STARTED | DB Placebo | 2 | |
| Double-blind Phase | STARTED | OL MA-CS 550 mg/Day | 0 | |
| Double-blind Phase | COMPLETED | DB MA-CS 550 mg/Day | 0 | |
| Double-blind Phase | COMPLETED | DB MA-CS 300 mg/Day | 0 | |
| Double-blind Phase | COMPLETED | DB Placebo | 1 | |
| Double-blind Phase | COMPLETED | OL MA-CS 550 mg/Day | 0 | |
| Double-blind Phase | NOT COMPLETED | DB MA-CS 550 mg/Day | 2 | |
| Double-blind Phase | NOT COMPLETED | DB MA-CS 300 mg/Day | 0 |
1 to 10 of 24Source ClinicalTrials.gov
See all 24 participant flowAdverse events48
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Insomnia | Psychiatric disorders | DB MA-CS 550 mg/Day | 0 | 2 | 0 |
| other | Insomnia | Psychiatric disorders | DB MA-CS 300 mg/Day | 0 | 0 | 0 |
| other | Insomnia | Psychiatric disorders | DB Placebo | 1 | 2 | 1 |
| other | Insomnia | Psychiatric disorders | OL MA-CS 550 mg/Day | 1 | 1 | 1 |
| other | Chest pain | General disorders | DB MA-CS 550 mg/Day | 0 | 2 | 0 |
| other | Chest pain | General disorders | DB MA-CS 300 mg/Day | 0 | 0 | 0 |
| other | Chest pain | General disorders | DB Placebo | 1 | 2 | 1 |
| other | Chest pain | General disorders | OL MA-CS 550 mg/Day | 1 | 1 | 1 |
| other | Vomiting | Gastrointestinal disorders | DB MA-CS 550 mg/Day | 0 | 2 | 0 |
| other | Vomiting | Gastrointestinal disorders | DB MA-CS 300 mg/Day | 0 | 0 | 0 |
1 to 10 of 48Source ClinicalTrials.gov
See all 48 adverse eventsAdverse event totals12
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | DB MA-CS 550 mg/Day | ||
| Total, all-cause mortality | DB MA-CS 300 mg/Day | ||
| Total, all-cause mortality | DB Placebo | ||
| Total, all-cause mortality | OL MA-CS 550 mg/Day | ||
| Total, other adverse events | DB MA-CS 550 mg/Day | 1 | 2 |
| Total, other adverse events | DB MA-CS 300 mg/Day | 0 | 0 |
| Total, other adverse events | DB Placebo | 2 | 2 |
| Total, other adverse events | OL MA-CS 550 mg/Day | 1 | 1 |
| Total, serious adverse events | DB MA-CS 550 mg/Day | 0 | 2 |
| Total, serious adverse events | DB MA-CS 300 mg/Day | 0 | 0 |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 adverse event totalsPapers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00637806
GET https://conductscience.org/api/trials/v1/NCT00637806/flow?page=2